Form 4 for DCTH DELCATH SYSTEMS, INC.
Accepted 2024-10-23 00:00:00 ET · period of report 2024-10-22 · accession 0001415889-24-025566 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-10-23 | 2024-10-22 | DCTH | MICHEL GERARD J | CEO, Dir | M - OptEx | $6.00 | +16.7K | 319.3K | +6% | +$100.0K |
| D | 2024-10-23 | 2024-10-22 | DCTH | MICHEL GERARD J | CEO, Dir | M - OptEx | $0.13 | -16.7K | 0 | -100% | -$2,167 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-22 | M | A | 16,666 | $6.00 | 319,334 | D | — | — | |
| 2 | Derivative | Tranche B Warrants to Purchase Common Stock | 2024-10-22 | M | D | 16,666 | $0.13 | 0 | D | $6.00 · 2023-03-29 to — | 16,666 Common Stock | (F3) The Tranche B Warrants were acquired in the issuer's private placement of common stock and warrants and issued as part of a unit with common stock and Tranche A Warrants. The per unit purchase price was $5.09, including a purchase price of $4.84 per share of common stock and $0.125 for each of the Tranche A and Tranche B Warrants. Each unit consisted of one share of common stock and an accompanying common stock warrant valued at 140% of the aggregate purchase price (the Tranche A Warrant) and an accompanying common stock warrant valued at 100% of the aggregate purchase price (the Tranche B Warrant). (F1) Immediately exercisable. (F2) The Tranche B Warrants expire the earlier of (i) twenty-one (21) days following the date of the Issuer's public announcement of record at least $10,000,000 in quarterly U.S. revenue from the commercialization of HEPZATO and (ii) March 31, 2026, provided, however, if the FDA Approval occurs on or before February 15, 2024 and the Tranche A Warrants have not been exercised in full on or before March 7, 2024, then the Tranche B Warrants shall automatically expire on March 8, 2024. The Issuer announced on October 17, 2024 that it had recorded at least $10,000,000 in quarterly U.S. revenue from the commercialization of HEPZATO and therefore such Tranche B Warrants expire on November 7, 2024. |